BVS: Bioventus Inc Price to Sales

Symbol and logo of brand Bioventus Inc (BVS)

Is it worth investing in Bioventus Inc. (BVS) amid recovering profitability and the expansion of biologics? This chart on GURU.Markets shows that the company's price-to-sales ratio has stabilized at 1.30. Proven orthobionic systems provide stable income, while the systematic update of the R&D pipeline in tissue regeneration ensures sustainable business growth without volatile swings.

BVS (Bioventus) P/S Multiple history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Bioventus Corp (BVS)

- market price and analyst price targets:
Stock Quotes bioventus.com|BVS - Analyst Consensus Forecast
- market capitalization information:
Market Value Bioventus Corp|BVS - Enterprise Value
- shareholders' equity book value data:
Equity per Share Bioventus|BVS - Book Capitalization|Market Capitalization to Book Value bioventus.com|BVS - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Bioventus Inc.|BVS - Long-Term Debt to Capital|Short-Term Debt to Capital Bioventus Global|BVS - Company Debts|Debt to Book Capitalization Ratio Bioventus Corp|BVS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Bioventus|Immediate Liquidity bioventus.com
- net income and valuation multiples indicators:
BVS - Company Net Income|Projected Net Profit Bioventus Inc.|BVS - Price to Earnings Ratio|Forward P/E Multiple Bioventus Inc|BVS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Bioventus Corp|BVS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Bioventus|BVS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months bioventus.com|BVS - Earnings growth in current year|Expected net earnings per share growth next year Bioventus Inc.
- issuer revenue and sales details:
BVS - Company Revenue|Company Revenue Forecast bioventus.com|BVS - Market Cap to Revenue|Price to Expected Revenue Ratio Bioventus Corp
Fundamental company analysis:bioventus.com BVS
Original product of Bioventus Corp

To minimize long-term risks, it is critical for investors to correlate market capitalization with actual sales volume, which is clearly demonstrated by the price-to-sales ratio. The stability of this metric for Bioventus Inc. (BVS) is supported by cost optimization through regulated production outsourcing, where the ratio of business value to revenue reflects a premium for operational efficiency and the absence of dependence on specific component suppliers.

Who Bioventus Inc. competes with

Market Cap to Revenue bostonscientific.com BSX|P/S Multiple EW (Edwards Lifesciences Corporation)|ResMed Inc (RMD) - Price to Sales|OmniPod - P/S Multiple|ZBH (Zimmer Biomet Holdings) - Market Cap to Revenue Ratio|COO: P/S Multiple|ALGN - Price-to-Revenue Coefficient|GMED (Globus Medical) - P/S Multiple|Market Cap to Revenue TransMedics Group Inc (TMDX)|P/S Multiple ATEC|P/S Multiple Artivion Corp (AORT)|Price-to-Revenue Ratio Enovis Corporation ENOV|integralife.com - Price-to-Revenue Ratio|ESTA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio BBNX (Beta Bionics, Inc.)|IRMD: P/S Multiple|Price to Sales Embecta Health (EMBC)|Price-to-Revenue Ratio Tandem Diabetes Care|AXGN - Price-to-Revenue Multiple|Market Cap to Revenue SIBN (SI-BONE)|P/S Multiple Orthofix Medical (OFIX)|P/S Multiple KIDS (OrthoPediatrics)|Price-to-Revenue Coefficient Treace Corp (TMCI)|SRTA - Price-to-Revenue Ratio|Price-to-Sales Ratio CARL|RxSight (RXST) - Price-to-Revenue Ratio|Market Cap to Revenue ClearPoint Neuro|STXS (Stereotaxis Corp) - P/S Multiple|Price to Sales Neuronetics, Inc STIM|Price-to-Revenue Ratio Sight Sciences, Inc. (SGHT)|orchestrabiomed.com - Market Cap to Revenue Ratio|Anika Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume NSPR (InspireMD Inc)|Jin Medical International Ltd - P/S Multiple|VANI: Price-to-Revenue Ratio|XTNT: P/S Multiple|NMTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Modular Medical Inc|Price to Sales Myomo Inc. MYO|Market Cap to Revenue COCH (Envoy Medical, Inc)|Price-to-Revenue Ratio VVOS (Vivos Therapeutics Inc)|P/S Multiple NVNO (enVVeno Medical)|Sintx Technologies Inc (SINT) - Price to Sales|TNON - Price-to-Revenue Ratio|LFWD (ReWalk Robotics) - Market Cap to Revenue Ratio|AMIX (autonomix.com) - Market Cap to Revenue|IVF: Market Cap to Sales Volume|Market Cap to Revenue BBLG|P/S Multiple axonics.com|Price-to-Revenue Ratio BIOLASE (BIOL)|Price-to-Revenue Coefficient dynatronics.com|Paragon 28 - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio INVO